170 related articles for article (PubMed ID: 19738461)
21. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
22. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB.
Dong GZ; Oh ET; Lee H; Park MT; Song CW; Park HJ
Exp Mol Med; 2010 May; 42(5):327-34. PubMed ID: 20200474
[TBL] [Abstract][Full Text] [Related]
23. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity.
Pink JJ; Planchon SM; Tagliarino C; Varnes ME; Siegel D; Boothman DA
J Biol Chem; 2000 Feb; 275(8):5416-24. PubMed ID: 10681517
[TBL] [Abstract][Full Text] [Related]
24. β-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes.
Park JS; Lee YY; Kim J; Seo H; Kim HS
Free Radic Biol Med; 2016 Aug; 97():168-178. PubMed ID: 27242267
[TBL] [Abstract][Full Text] [Related]
25. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
[TBL] [Abstract][Full Text] [Related]
26. Expressions of some antioxidant genes in SH-SY5Y cells treated with β-lapachone, morphine and electromagnetic field.
Mahmoudinasab H; Saadat M
Mol Biol Rep; 2018 Jun; 45(3):379-387. PubMed ID: 29611025
[TBL] [Abstract][Full Text] [Related]
27. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
28. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
29. β-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol.
Steinmeier J; Kube S; Karger G; Ehrke E; Dringen R
Neurochem Res; 2020 Oct; 45(10):2442-2455. PubMed ID: 32789798
[TBL] [Abstract][Full Text] [Related]
30. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
[TBL] [Abstract][Full Text] [Related]
31. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
32. Following anticancer drug activity in cell lysates with DNA devices.
Kahanda D; Singh N; Boothman DA; Slinker JD
Biosens Bioelectron; 2018 Nov; 119():1-9. PubMed ID: 30098460
[TBL] [Abstract][Full Text] [Related]
33. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
34. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
36. Protective role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cisplatin-induced nephrotoxicity.
Gang GT; Kim YH; Noh JR; Kim KS; Jung JY; Shong M; Hwang JH; Lee CH
Toxicol Lett; 2013 Aug; 221(3):165-75. PubMed ID: 23831944
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro.
Suzuki M; Amano M; Choi J; Park HJ; Williams BW; Ono K; Song CW
Radiat Res; 2006 May; 165(5):525-31. PubMed ID: 16669706
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological activation of NQO1 increases NAD⁺ levels and attenuates cisplatin-mediated acute kidney injury in mice.
Oh GS; Kim HJ; Choi JH; Shen A; Choe SK; Karna A; Lee SH; Jo HJ; Yang SH; Kwak TH; Lee CH; Park R; So HS
Kidney Int; 2014 Mar; 85(3):547-60. PubMed ID: 24025646
[TBL] [Abstract][Full Text] [Related]
39. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines.
Arakawa N; Okubo A; Yasuhira S; Takahashi K; Amano H; Akasaka T; Masuda T; Shibazaki M; Maesawa C
Oncol Lett; 2018 Feb; 15(2):2393-2400. PubMed ID: 29434949
[TBL] [Abstract][Full Text] [Related]
40. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
